ATDC/TRIM29 drives invasive bladder cancer formation through miRNA-mediated and epigenetic mechanisms

Cancer Research

Volumn 75, Issue 23, 2015, Pages 5155-5166

  Palmbos, Phillip L ^a,b   Wang, Lidong ^b   Yang, Huibin ^b   Wang, Yin ^b   Leflein, Jacob ^b   Ahmet, McKenzie L ^b   Wilkinson, John E ^b   Kumar Sinha, Chandan ^b   Ney, Gina M ^b   Tomlins, Scott A ^b   Daignault, Stephanie ^b   Kunju, Lakshmi P ^b   Wu, Xue Ru ^c   Lotan, Yair ^d   Liebert, Monica ^b   Ljungman, Mats E ^b   Simeone, Diane M ^b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATAXIA TELANGIECTASIA GROUP D COMPLEMENTING PROTEIN; DNA; DNA METHYLTRANSFERASE 3A; MEMBRANE PROTEIN; MICRORNA; MICRORNA 29; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN TRIM29; UNCLASSIFIED DRUG; DNA (CYTOSINE 5) METHYLTRANSFERASE; DNA BINDING PROTEIN; PTEN PROTEIN, HUMAN; PTEN PROTEIN, MOUSE; TRANSCRIPTION FACTOR; TRIM29 PROTEIN, HUMAN; TRIM29 PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATDC GENE; BLADDER CANCER; BLADDER CARCINOGENESIS; CONTROLLED STUDY; DNA METHYLATION; EPIGENETICS; FEMALE; GENE FUNCTION; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE; TRIM29 GENE; TUMOR INVASION; TUMOR XENOGRAFT; UPREGULATION; ANIMAL; BIOSYNTHESIS; BLADDER TUMOR; DISEASE MODEL; GENE EXPRESSION; GENETIC EPIGENESIS; GENETIC TRANSFECTION; GENETICS; METABOLISM; NONOBESE DIABETIC MOUSE; PATHOLOGY; SCID MOUSE; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; DNA-BINDING PROTEINS; EPIGENESIS, GENETIC; FEMALE; GENE EXPRESSION; HUMANS; MICE; MICE, INBRED NOD; MICE, SCID; MICE, TRANSGENIC; MICRORNAS; NEOPLASM INVASIVENESS; PTEN PHOSPHOHYDROLASE; TRANSCRIPTION FACTORS; TRANSFECTION; UP-REGULATION; URINARY BLADDER NEOPLASMS;

EID: 84955282032     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-15-0603     Document Type: Article

References (46)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012; 62: 10-29.
2. Burger M, Catto JW,DalbagniG,Grossman HB, Herr H, Karakiewicz P, et al. Epidemiology and risk factors of urothelial bladder cancer. Eur Urol 2013; 63: 234-41.
3. Dinney CP, McConkey DJ, Millikan RE, Wu X, Bar-Eli M, Adam L, et al. Focus on bladder cancer. Cancer Cell 2004; 6: 111-6.
4. Wu X-R. Urothelial tumorigenesis: A tale of divergent pathways. Nat Rev Cancer 2005; 5: 713-25.
5. Platt FM, Hurst CD, Taylor CF, Gregory WM, Harnden P, Knowles MA. Spectrum of phosphatidylinositol 3-kinase pathway gene alterations in bladder cancer. Clin Cancer Res 2009; 15: 6008-17.
6. Iyer G, Al-AhmadieH, Schultz N, Hanrahan AJ,Ostrovnaya I, Balar AV, et al. Prevalence and co-occurrence of actionable genomic alterations in highgrade bladder cancer. J Clin Oncol 2013; 31: 3133-40.
7. Network TCGAR. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 2014; 507: 315-22.
8. Choi W, Czerniak B, Ochoa A, Su X, Siefker-Radtke A, Dinney C, et al. Intrinsic basal and luminal subtypes of muscle-invasive bladder cancer. Nat Rev Urol 2014; 11: 400-10.
9. Damrauer JS, Hoadley KA, Chism DD, Fan C, Tiganelli CJ, Wobker SE, et al. Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology. Proc Natl Acad Sci U S A 2014; 111: 3110-5.
10. Hoadley KA, Yau C, Wolf DM, Cherniack AD, Tamborero D, Ng S, et al. Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin. Cell 2014; 158: 929-44.
11. Zhang ZT, Pak J, Huang HY, Shapiro E, Sun TT, Pellicer A, et al. Role of Haras activation in superficial papillary pathway of urothelial tumor formation. Oncogene 2001; 20: 1973-80.
12. Mo L, Zheng X, Huang HY, Shapiro E, Lepor H, Cordon-Cardo C, et al. Hyperactivation of Ha-ras oncogene, but not Ink4a/Arf deficiency, triggers bladder tumorigenesis. J Clin Invest 2007; 117: 314-25.
13. Ahmad I, Morton JP, Singh LB, Radulescu SM, Ridgway RA, Patel S, et al. b-Catenin activation synergizes with PTEN loss to cause bladder cancer formation. Oncogene 2010; 30: 178-89.
14. Ahmad I, Patel R, Liu Y, Singh LB, Taketo MM, Wu XR, et al. Ras mutation cooperates with b-catenin activation to drive bladder tumourigenesis. Cell Death Dis 2011; 2: E124.
15. He F,MoL, Zheng XY,HuC, Lepor H, Lee EY, et al. Deficiency of pRb family proteins and p53 in invasive urothelial tumorigenesis. Cancer Res 2009; 69: 9413-21.
16. Puzio-Kuter AM, Castillo-Martin M, Kinkade CW, Wang X, Shen TH, Matos T, et al. Inactivation of p53 and Pten promotes invasive bladder cancer. Genes Dev 2009; 23: 675-80.
17. Rampias T, Vgenopoulou P, Avgeris M, Polyzos A, Stravodimos K, Valavanis C, et al. A new tumor suppressor role for the Notch pathway in bladder cancer. Nat Med 2014; 20: 1199-205.
18. Dyrskjot L, Kruhoffer M, Thykjaer T, Marcussen N, Jensen JL, Moller K, et al. Gene expression in the urinary bladder: A common carcinoma in situ gene expression signature exists disregarding histopathological classification. Cancer Res 2004; 64: 4040-8.
19. Wang L, Heidt DG, Lee CJ, Yang H, Logsdon CD, Zhang L, et al. Oncogenic function of ATDC in pancreatic cancer through Wnt pathway activation and beta-catenin stabilization. Cancer Cell 2009; 15: 207-19.
20. Yuan Z, Villagra A, Peng L, Coppola D, Glozak M, Sotomayor EM, et al. The ATDC (TRIM29) protein binds p53 and antagonizes p53-mediated functions. Mol Cell Biol 2010; 30: 3004-15.
21. Asangani IA, Ateeq B, Cao Q, Dodson L, Pandhi M, Kunju LP, et al. Characterization of the EZH2-MMSET histone methyltransferase regulatory axis in cancer. Mol Cell 2013; 49: 80-93.
22. Udager AM, Shi Y, Tomlins SA, Alva A, Siddiqui J, Cao X, et al. Frequent discordance between ERG gene rearrangement and ERG protein expression in a rapid autopsy cohort of patients with lethal, metastatic, castrationresistant prostate cancer. Prostate 2014; 74: 1199-208.
23. Tseng-Rogenski S, Lee IL, Gebhardt D, Fischer SM, Wood C, Park JM, et al. Loss of 15-hydroxyprostaglandin dehydrogenase expression disrupts urothelial differentiation. Urology 2008; 71: 346-50.
24. DeGraff DJ, Robinson VL, Shah JB, Brandt WD, Sonpavde G, Kang Y, et al. Current preclinical models for the advancement of translational bladder cancer research. Mol Cancer Ther 2013; 12: 121-30.
25. Seager C, Puzio-Kuter AM, Cordon-Cardo C, McKiernan J, Abate-Shen C. Mouse models of human bladder cancer as a tool for drug discovery. Curr Protoc Pharmacol 2010; Chapter 14: Unit14.14.
26. Logsdon CD, Simeone DM, Binkley C, Arumugam T, Greenson JK, Giordano TJ, et al. Molecular profiling of pancreatic adenocarcinoma and chronic pancreatitis identifies multiple genes differentially regulated in pancreatic cancer. Cancer Res 2003; 63: 2649-57.
27. Rhodes DR, Kalyana-Sundaram S, Tomlins SA, Mahavisno V, Kasper N, Varambally R, et al. Molecular concepts analysis links tumors, pathways, mechanisms, and drugs. Neoplasia 2007; 9: 443-54.
28. Oncomine. www.oncomine.com.
29. Su AI, Welsh JB, Sapinoso LM, Kern SG, Dimitrov P, Lapp H, et al. Molecular classification of human carcinomas by use of gene expression signatures. Cancer Res 2001; 61: 7388-93.
30. Sanchez-Carbayo M, Socci ND, Lozano J, Saint F, Cordon-Cardo C. Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays. J Clin Oncol 2006; 24: 778-89.
31. Masuda Y, Takahashi H, Sato S, Tomomori-Sato C, Saraf A, Washburn MP, et al. TRIM29 regulates the assembly of DNA repair proteins into damaged chromatin. Nat Commun 2015; 6: 7299.
32. Wu Y, Siadaty MS, Berens ME, Hampton GM, Theodorescu D. Overlapping gene expression profiles of cellmigration and tumor invasion in human bladder cancer identify metallothionein 1E and nicotinamide N-methyltransferase as novel regulators of cell migration. Oncogene 2008; 27: 6679-89.
33. Tsuruta H, Kishimoto H, Sasaki T, Horie Y, Natsui M, Shibata Y, et al. Hyperplasia and carcinomas in Pten-deficient mice and reduced PTEN protein in human bladder cancer patients. Cancer Res 2006; 66: 8389-96.
34. Hollander MC, Blumenthal GM, Dennis PA. PTEN loss in the continuum of common cancers, rare syndromes and mouse models. Nat Rev Cancer 2011; 11: 289-301.
35. Dai F, Zhang Y, Zhu X, Shan N, Chen Y. Anticancer role of MUC1 aptamermiR- 29b chimera in epithelial ovarian carcinoma cells through regulation of PTEN methylation. Target Oncol 2012; 7: 217-25.
36. Chedin F. The DNMT3 family of mammalian de novo DNA methyltransferases. Prog Mol Biol Transl Sci 2011; 101: 255-85.
37. Zhao Z, Wu Q, Cheng J, Qiu X, Zhang J, Fan H. Depletion of DNMT3A suppressed cell proliferation and restored PTEN in hepatocellular carcinoma cell. J Biomed Biotechnol 2010; 2010: 737535.
38. Fabbri M, Garzon R, Cimmino A, Liu Z, Zanesi N, Callegari E, et al. MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proc Natl Acad Sci U S A 2007; 104: 15805-10.
39. Morita S, Horii T, KimuraM,Ochiya T, Tajima S, Hatada I.miR-29 represses the activities of DNA methyltransferases and DNA demethylases. Int J Mol Sci 2013; 14: 14647-58.
40. Mott JL, Kurita S, Cazanave SC, Bronk SF, Werneburg NW, Fernandez- Zapico ME. Transcriptional suppression of mir-29b-1/mir-29a promoter by c-Myc, hedgehog, and NF-kappaB. J Cell Biochem 2010; 110: 1155-64.
41. Zhang X, Zhao X, Fiskus W, Lin J, Lwin T, Rao R, et al. Coordinated silencing of MYC-mediated miR-29 by HDAC3 and EZH2 as a therapeutic target of histone modification in aggressive B-Cell lymphomas. Cancer Cell 2012; 22: 506-23.
42. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009; 59: 225-49.
43. Shin K, Lim A, Odegaard JI, Honeycutt JD, Kawano S, Hsieh MH, et al. Cellular origin of bladder neoplasia and tissue dynamics of its progression to invasive carcinoma. Nat Cell Biol 2014; 16: 469-78.
44. Van Batavia J, Yamany T,Molotkov A, Dan H, MansukhaniM, Batourina E, et al. Bladder cancers arise from distinct urothelial sub-populations. Nat Cell Biol 2014; 16: 982-91.
45. Sandhu R, Rivenbark AG, Mackler RM, Livasy CA, Coleman WB. Dysregulation of microRNA expression drives aberrant DNA hypermethylation in basal-like breast cancer. Int J Oncol 2014; 44: 563-72.
46. Fristrup N, Birkenkamp-Demtröder K, Reinert T, Sanchez-Carbayo M, Segersten U, Malmström PU, et al. Multicenter validation of cyclin D1, MCM7, TRIM29, and UBE2C as prognostic protein markers in non-muscleinvasive bladder cancer. Am J Pathol 2013; 182: 339-49.